Surrozen

Executive Summary

Surrozen is a private biotechnology company pioneering a novel class of Wnt-based antibody therapeutics for tissue repair and regeneration. Founded in 2015 by leading scientists in Wnt signaling, the company leverages its proprietary platform to precisely modulate this critical pathway, with an initial focus on sight-threatening ophthalmic diseases that lack effective treatments. Surrozen’s approach aims to harness the regenerative potential of Wnt signaling to restore damaged tissues, addressing high unmet medical needs in ophthalmology. While the company remains in early clinical stages, its technology has attracted attention for its potential to unlock a new paradigm in regenerative medicine. Surrozen is headquartered in South San Francisco, California, and operates as a private entity with limited public financial disclosures. The company’s progress in advancing its lead candidate through clinical development will be key to validating its platform and driving future value.

Upcoming Catalysts (preview)

• H2 2026Phase 1/2 Clinical Data for Lead Ophthalmic Candidate40% success
• 2026Partnership or Licensing Agreement for Wnt Platform50% success
• 2026Additional Financing Round to Extend Runway70% success